Top 10 A+ RISK-OFF — ASML, SMH, CAT, LLY, ABBV, EWY, VRTX, IBB, UNH, NVO

🟠 EARLY RISK-OFF — Defensive Momentum + Volatility Compression — Regime shifted from NEUTRAL (50) to EARLY RISK-OFF (38) as ensemble model probability reaches 0.4095. NASDAQ -1.32% leads tech selloff while value/defensive sectors outperform. VIX 17.28 (+3%). Strategy: 90% Momentum, 10% Pre-Squeeze. Breakout BLOCKED (ERO > 0.40). Pullback BLOCKED. R/R ≥ 2.0, Horizon H15. Sizing ×0.7 regime-rotation-penalty (3× regime changes in 5 days). Healthcare + semis + industrials dominate in quality-over-quantity approach.

⚠ Regime Shift: NEUTRAL → EARLY RISK-OFF: Ensemble model classifies EARLY RISK-OFF as dominant regime (probability 0.4095 > risk_on 0.333 > neutral 0.176). Score dropped from 50 (NEUTRAL) to 38. Three regime changes in 5 scanner days triggers regime-rotation-penalty: all sizing ×0.7. Only Momentum and Pre-Squeeze strategies allowed. R/R minimum 2.0, Horizon H15.

Regime score 38 — classifié EARLY RISK-OFF. L’ensemble model retourne : early_risk_off 0.4095 (dominant), risk_on 0.333, neutral 0.176, crisis 0.082. Per la règle regime-score-label-lag : score < 40 = ERO regardless of label. Oscillation régime détectée (3× en 5 jours : RISK-ON → ERO → NEUTRAL → ERO) → sizing ×0.7 regime-rotation-penalty. Strategy weights : Momentum 90%, Pre-Squeeze 10%. Breakout exclu (ERO > 0.40 per rule breakout-early-risk-off-block). Pullback exclu (sustained ERO). Energy exclu. R/R minimum 2.0 (H15, per rule rr-min-by-regime). VIX 17.28 — still below 28 defensive tilt threshold but trending up.

Session strategy: Le scan de mardi est structuré autour de trois axes défensifs : (1) Healthcare momentum — LLY, ABBV, VRTX, UNH et IBB capturent la rotation défensive. Le healthcare est le secteur le plus performant en EARLY RISK-OFF avec des corrélations intra-sectorielles faibles (max 0.50 ABBV-VRTX). (2) Semiconductor quality — ASML et SMH restent en momentum malgré le regime shift, portés par le peace dividend et le cycle AI capex structurel. MU earnings mercredi = catalyseur. (3) Diversification géographique — NVO (EU, pre-squeeze near 200DMA) et EWY (APAC, near ATH) complètent la couverture. CAT (industrials, ATH) apporte une décorrélation sectorielle essentielle. Zéro Breakout (ERO > 0.40), zéro Pullback, zéro Energy.

Tuesday, June 23, 2026

Market Regime: RISK-OFF (Score 0.38)

Market Snapshot (Tuesday, June 23, 2026)

Index / Asset	Price	Change	Signal
S&P 500	7,472.79	-0.37%	Mild pullback from 7,500 🟡
Nasdaq Composite	26,166.60	-1.32%	Tech selloff — growth rotation 🔴
Dow Jones	51,712.71	+0.29%	Value outperformance ✅
Russell 2000	3,004.40	+0.83%	Small-cap strength ✅
VIX	17.28	+3.0%	Rising but sub-20 🟡
DXY (Dollar)	101.00	+0.15%	Dollar stable 🟡
Gold	$4,209.70	-0.85%	Risk-on unwind continues
WTI Crude Oil	$74.08	-2.33%	Iran peace supply expansion 🔴
10Y Treasury (TLT)	$86.09	-0.76%	Yields rising 🟡

Why EARLY RISK-OFF demands R/R ≥ 2.0 and H15 horizon

In EARLY RISK-OFF, institutional buyers step back from aggressive entries. Breakout strategies fail systematically (0% win rate across 3 consecutive retros in ERO). The R/R 2.0 minimum compensates for lower hit rate by ensuring each winner covers two losers. The H15 horizon (vs H10 in NEUTRAL) gives positions more time to develop since moves are slower in defensive regimes. Historical evidence: ERO regimes with R/R < 2.0 produced 8 consecutive stops in Jun 1-3 (the D* grade week). Tightening the quality filter is not conservative — it is the mathematically optimal response to lower-probability setups.

Macro Context — Week of Tuesday, June 23, 2026

Global Events Calendar

Date	Event	Impact	Direction Risk
Tue Jun 23	FDX Earnings (AMC)	Medium	Transport/logistics bellwether — 7.8% implied move
Tue Jun 23	CCL Earnings (BMO)	Low	Consumer discretionary read
Tue Jun 23	Existing Home Sales	Medium	Housing market health check
Wed Jun 24	MU (Micron) Earnings (AMC)	HIGH	AI memory demand — catalyst for SMH, ASML. 13.1% implied move
Wed Jun 24	New Home Sales	Medium	Housing pipeline
Thu Jun 25	GDP Q1 Final Revision	HIGH	Growth confirmation — negative revision hits cyclicals (CAT)
Thu Jun 25	Durable Goods Orders	HIGH	Capex health — CAT and industrials sensitive
Fri Jun 26	Core PCE Price Index	HIGH	Fed preferred inflation gauge — hot print = rate fears
Fri Jun 26	Consumer Sentiment (Final)	Medium	Post-peace deal consumer confidence

Sector Rotation Scorecard

Sector (ETF)	Week Performance	Regime Signal	Our Exposure
Healthcare (XLV)	+0.88%	Defensive leadership in ERO	LLY #4, ABBV #5, VRTX #7, UNH #9, IBB #8
Semiconductors (SOX)	+1.37%	AI capex cycle momentum persists	ASML #1, SMH #2, EWY #6 (Samsung/SK Hynix)
Industrials (XLI)	+1.2%	Infrastructure cycle — CAT at ATH	CAT #3
Technology (XLK)	-1.32%	Selloff — growth rotation out	No direct exposure (NASDAQ -1.32%)
Energy (XLE)	-2.0%	Iran peace supply expansion	No exposure (ERO + energy filter active)
Materials (XLB)	-0.9%	Gold/copper selling pressure	No exposure
Financials (XLF)	+0.5%	Moderate — yield curve normalization	No direct equity exposure (UNH is healthcare/insurance)
Consumer Staples (XLP)	+0.2%	Flat — defensive but no catalyst	No exposure

Week-Ahead Thesis

Le regime EARLY RISK-OFF restructure le portefeuille vers la qualité défensive cette semaine. Trois dynamiques : (1) Healthcare momentum défensif — le secteur surperforme en ERO avec des corrélations intra faibles. LLY (GLP-1), ABBV (immunologie), VRTX (thérapie génique) et UNH (managed care) offrent une diversification réelle malgré l’optique sectorielle. (2) Semiconductor structural momentum — ASML et SMH maintiennent le momentum sur le cycle AI capex multi-années, indépendant du regime court-terme. MU earnings mercredi = catalyseur binaire. (3) Horizon H15 + R/R 2.0 — en ERO, chaque setup doit payer 2× le risque pour compenser le hit rate réduit. Le Core PCE vendredi est le risque clé de la semaine : un chiffre chaud (> 0.3% MoM) pourrait accélérer la transition vers RISK-OFF.

ASML

ASML — ASML Holding N.V.

Semiconductor Equipment • NASDAQ (Dutch ADR) • ~$744B mcap

$1,929.25

-0.02%

Europe 🇪🇺 Momentum Score 93 EUV MonopolyNear 52W High ☪ Halal

ASML détient le monopole absolu sur la lithographie EUV — aucun concurrent viable. RSI 65.7 en zone de momentum optimale sans surextension. MACD +96.86 montre un spread massif au-dessus du signal, confirmant une tendance haussière soutenue. Le peace dividend SOX (+6.4%) continue de bénéficier au leader de l’équipement semi-conducteur. Near 52W high à $1,958 avec breakout territory en vue. La corrélation modérée avec SMH (0.83) offre une exposition semis complémentaire sans redondance totale. Anti-dilution clean (aucun flag MCP).

✅ Confirmations

Above all EMAs (20/50/200) with RSI 65.7 — momentum sweet spot
MACD +96.86 — massive bullish spread over signal line
EUV monopoly with zero viable competitor — structural moat
Peace dividend SOX rotation continues — geopolitical risk premium removal
Near 52W high at $1,958 — breakout territory with institutional flow

❌ Invalidations

EARLY RISK-OFF regime — institutional participation may thin
SMH correlation 0.83 — double semis exposure in portfolio
China EUV export scrutiny — regulatory headline risk
6.5% stop distance — wider than ideal in ERO environment
MU earnings Wed — sector event risk within H15 horizon

Entry: $1,915–$1,940

Stop Loss: $1,803.00

TP1: $2,181.00

TP2: $2,307.00

R/R: 1:2.0

Horizon: 15 days

SMH

SMH — VanEck Semiconductor ETF

Semiconductor ETF • NASDAQ • NVDA, TSM, AVGO, ASML weighted

$668.91

+1.37%

ETF 📊 Momentum Score 93 All-Time HighAI Capex Cycle ☪ Halal

SMH est à son plus haut historique ($671.83), confirmant le momentum structurel du secteur semi-conducteurs. RSI 65.4 en zone de tendance forte sans être en surachat. 22% au-dessus de la 200DMA — forte tendance mais l’ATH élimine la résistance au-dessus. Le cycle AI capex multi-années (NVDA, TSM, AVGO = top holdings) offre un catalyseur structurel indépendant du régime court-terme. MU earnings mercredi = catalyseur binaire direct pour le panier SMH. ETF = zéro risque de dilution, liquidité massive.

✅ Confirmations

At all-time high $671.83 — no overhead resistance, clean breakout
Above all EMAs with 22% distance from 200DMA — strong trend
RSI 65.4 — momentum without overbought territory
MACD +26.59 — sustained trending signal
SOX +6.4% peace dividend momentum continuation

❌ Invalidations

ASML correlation 0.83 — overlapping semis exposure
EWY correlation 0.86 — portfolio sizing reduced on EWY
ATH entry carries reversal risk in EARLY RISK-OFF
Concentrated NVDA/TSM/AVGO weighting — single-name risk
MU earnings Jun 24 — sector event risk within horizon

Entry: $665–$675

Stop Loss: $628.00

TP1: $751.00

TP2: $792.00

R/R: 1:2.0

Horizon: 15 days

CAT

CAT — Caterpillar Inc.

Heavy Equipment / Industrials • NYSE • ~$471B mcap

$1,022.28

+3.70%

US 🇺🇸 Momentum Score 92 All-Time HighInfrastructure Cycle ☪ Halal

Caterpillar atteint un nouveau plus haut historique à $1,023.25 (+3.70% sur la journée). RSI 69.6 montre un momentum fort juste en dessous du seuil de surachat (72). MACD +28.57 avec un spread large au-dessus du signal. Le cycle infrastructure (CHIPS Act, IRA, AI data center capex) alimente la demande d’équipements lourds. Seul pick industrials du portefeuille — corrélation faible avec le bloc healthcare (max rho 0.44 avec LLY). 16.8% au-dessus de la 50DMA, en dessous du cap stratégique de 20%.

✅ Confirmations

New 52W high at $1,023.25 — fresh breakout with institutional flow
RSI 69.6 strong momentum (below 72 overbought threshold)
MACD +28.57 with wide spread — sustained trend confirmation
Infrastructure cycle: CHIPS Act + IRA + AI data center capex
Sector diversifier — only industrials pick, low correlation with healthcare

❌ Invalidations

RSI 69.6 approaching overbought — momentum exhaustion risk
16.8% distance from 50DMA — extended (cap 20%)
GDP Q1 Final Thursday — negative revision hits cyclicals
ERO regime — cyclicals historically underperform in risk-off transitions
Durable Goods Orders Thursday — additional cyclical data point

Entry: $1,015–$1,030

Stop Loss: $971.00

TP1: $1,124.00

TP2: $1,175.00

R/R: 1:2.0

Horizon: 15 days

LLY

LLY — Eli Lilly and Company

Pharmaceutical / GLP-1 • NYSE • ~$983B mcap

$1,102.08

+0.32%

US 🇺🇸 Momentum Score 92 GLP-1 LeaderDefensive Healthcare ☪ Halal

LLY est le leader GLP-1 (Mounjaro/Zepbound) avec un RSI 55.1 en zone d’entrée optimale — pas d’extension excessive. MACD +28.04 confirme une tendance haussière soutenue. Au-dessus de toutes les EMAs avec 5.2% de distance par rapport à la 50DMA. Le healthcare défensif surperforme historiquement en EARLY RISK-OFF. La corrélation négative avec SMH (-0.07) offre une couverture naturelle dans le portefeuille. Franchise $50B+ de revenus annualisés en croissance rapide.

✅ Confirmations

RSI 55.1 — optimal momentum entry without overextension
GLP-1 juggernaut: Mounjaro/Zepbound $50B+ revenue trajectory
MACD +28.04 — strong sustained trend above signal
Above 50DMA by 5.2% — healthy positioning
Defensive healthcare outperforms in EARLY RISK-OFF regime

❌ Invalidations

TP1 at $1,204 exceeds 52W high ($1,182.73) — uncharted territory
Healthcare concentration — 3 pharma/biotech picks in portfolio
Core PCE Friday — inflation surprise rotates out of growth pharma
ERO regime sizing ×0.7 limits position size
Political scrutiny on GLP-1 pricing — headline risk

Entry: $1,090–$1,110

Stop Loss: $1,051.00

TP1: $1,204.00

TP2: $1,255.00

R/R: 1:2.0

Horizon: 15 days

ABBV

ABBV — AbbVie Inc.

Pharmaceutical / Immunology • NYSE • ~$406B mcap

$230.01

+6.25%

US 🇺🇸 Momentum Score 91 Institutional SurgeDividend 2.4% ☪ Halal

ABBV surged +6.25% on institutional buying, confirming le pivot post-Humira. Skyrizi ($11B run-rate) et Rinvoq ($5.5B) compensent la baisse Humira avec des marges supérieures. RSI 62.4 montre un momentum en construction sans surextension. Au-dessus de toutes les EMAs avec MACD positif. Dividend yield 2.4% offre un plancher de revenus défensif. Corrélation modérée avec LLY (0.36) et VRTX (0.50) — différenciation thérapeutique réelle.

✅ Confirmations

+6.25% surge day — high-conviction institutional buying
RSI 62.4 — momentum building without overextension
Above all EMAs with MACD positive — trend confirmed
Skyrizi/Rinvoq diversification beyond Humira working
Dividend yield 2.4% — income floor for defensive positioning

❌ Invalidations

One-day surge may need consolidation before entry
TP1 at $248 exceeds 52W high ($244.81) — resistance zone
Healthcare sector overlap with LLY (rho 0.36) and VRTX (rho 0.50)
Humira biosimilar erosion continues — revenue transition risk
Debt/mcap ratio elevated — monitor for sharia threshold

Entry: $228–$232

Stop Loss: $221.00

TP1: $248.00

TP2: $258.00

R/R: 1:2.0

Horizon: 15 days

EWY

EWY — iShares MSCI South Korea ETF

South Korea ETF • NYSE • Samsung, SK Hynix, Hyundai weighted

$219.02

-0.08%

APAC 🌏 Momentum Score 91 Near 52W HighAPAC Diversifier CONV

EWY est à proximité de son plus haut 52 semaines ($220.89) avec un momentum fort. Samsung Electronics (~25% du panier) et SK Hynix (~8%) offrent une exposition directe au cycle AI memory. Au-dessus de toutes les EMAs avec 66% de distance par rapport à la 200DMA. MACD +8.88 confirme la tendance. La faiblesse du won (USDJPY 161.5) soutient les exportateurs coréens. Diversificateur géographique APAC essentiel pour le portefeuille.

✅ Confirmations

Near 52W high at $220.89 — breakout imminent
Above all EMAs with 66% above 200DMA — very strong trend
MACD +8.88 — confirmed uptrend
Samsung + SK Hynix = AI memory semiconductor exposure
Won weakness supports Korean exporters — FX tailwind

❌ Invalidations

Correlation with SMH 0.86 — sizing reduced ×0.5 (overlapping semis)
7.6% stop distance — near maximum 8% bound
Contains Korean banks (KB Financial, Shinhan) — non-sharia
China economic weakness — Korean export drag
Hang Seng -0.65% — regional Asian sentiment mixed

Entry: $216–$222

Stop Loss: $203.00

TP1: $252.00

TP2: $269.00

R/R: 1:2.0

Horizon: 15 days

VRTX

VRTX — Vertex Pharmaceuticals

Biotechnology / Cystic Fibrosis • NASDAQ • ~$119B mcap

$466.79

+3.36%

US 🇺🇸 Momentum Score 90 Gene Therapy PipelineNear 52W High ☪ Halal

Vertex Pharmaceuticals est en momentum fort avec RSI 63.6 et MACD +5.26 au-dessus du signal. Au-dessus de toutes les EMAs. Casgevy (première thérapie génique CRISPR approuvée) et Journavx (douleur non-opioïde) diversifient au-delà de la franchise CF historique. TP1 à $503 est stratégiquement placé juste en dessous du 52W high ($507.92), un niveau de résistance naturel. Low-beta biotech défensif qui performe bien en EARLY RISK-OFF.

✅ Confirmations

RSI 63.6 — strong momentum, well below overbought
Above all EMAs with MACD +5.26 positive
Casgevy (gene therapy) + Journavx (pain) diversifying revenue
TP1 at $503 just below 52W high $507.92 — natural target
Low-beta defensive biotech — outperforms in ERO

❌ Invalidations

Healthcare concentration — 3rd pharma/biotech individual pick
$119B mcap — mid-large cap with higher vol than mega-caps
Patent cliff concerns on CF franchise long-term
Core PCE Friday — healthcare sector event risk
ABBV correlation 0.50 — moderate intra-sector overlap

Entry: $463–$470

Stop Loss: $449.00

TP1: $503.00

TP2: $521.00

R/R: 1:2.0

Horizon: 15 days

IBB

IBB — iShares Biotechnology ETF

Biotechnology ETF • NASDAQ • AMGN, GILD, REGN, VRTX weighted

$177.00

+1.94%

ETF 📊 Momentum Score 89 Near 52W HighDefensive Sector CONV

IBB est proche de son plus haut 52 semaines ($179.64) avec le secteur biotech en rotation défensive. Le panier diversifié (AMGN, GILD, REGN, VRTX) réduit le risque id de single-name. Au-dessus de toutes les EMAs avec MACD positive. RSI 62 montre un momentum sain. Le healthcare défensif surperforme en EARLY RISK-OFF historiquement. ETF = zéro risque dilution, liquidité élevée.

✅ Confirmations

Near 52W high $179.64 — broad biotech sector strength
RSI 62.0 — healthy momentum, no overextension
Above all EMAs with MACD positive
Diversified basket reduces single-stock biotech risk
Defensive sector rotation into healthcare in ERO regime

❌ Invalidations

MACD spread only +1.19 — weaker momentum signal vs other picks
3.1% stop distance — tight, near minimum 3% bound
Contains names overlapping with LLY, ABBV, VRTX positions
Healthcare sector concentration adds to portfolio weight
Non-sharia (contains mixed healthcare/insurance names)

Entry: $175–$179

Stop Loss: $171.50

TP1: $188.00

TP2: $194.00

R/R: 1:2.0

Horizon: 15 days

UNH

UNH — UnitedHealth Group

Health Insurance / Managed Care • NYSE • ~$369B mcap

$406.68

+1.43%

US 🇺🇸 Momentum Score 88 Recovery MomentumPortfolio Decorrelator CONV

UNH est en forte recovery depuis le creux de $234 (+74%) et approche son 52W high à $415.98. Au-dessus de toutes les EMAs avec RSI 62.2 montrant un momentum soutenu. Optum Health Services diversifie au-delà de l’assurance pure. Corrélation très faible avec les autres picks (rho avg ~0.05) — excellent décorrélateur de portefeuille. La managed care performe bien en ERO car les revenus sont récurrents et prévisibles.

✅ Confirmations

Above all EMAs — sustained recovery from $234 low
RSI 62.2 — momentum building after deep drawdown
Near 52W high $415.98 — potential breakout
Optum diversification — tech-enabled healthcare services
Near-zero correlation with other picks — portfolio decorrelator

❌ Invalidations

MACD 9.50 below signal 10.68 — bearish crossover warning
DOJ investigation headline risk — regulatory overhang
Non-sharia compliant (conventional insurance — interest-based)
Change Healthcare breach aftermath — reputational risk
Healthcare concentration — 5th healthcare-adjacent pick

Entry: $403–$410

Stop Loss: $393.00

TP1: $435.00

TP2: $449.00

R/R: 1:2.0

Horizon: 15 days

NVO

NVO — Novo Nordisk A/S

Pharmaceutical / GLP-1 • NYSE (Danish ADR) • ~$203B mcap

$45.88

+6.23%

Europe 🇪🇺 Pre-Squeeze Score 86 Pre-SqueezeEU DiversifierGLP-1 Recovery ☪ Halal

NVO est en pre-squeeze avec une compression de volatilité (ATR 3.25%) et un MACD qui vient de croiser en positif. Le surge de +6.23% sur un volume de 17M actions confirme un intérêt institutionnel renouvelé. Au-dessus des EMA20 ($43.74) et EMA50 ($43.32), approchant la EMA200 à $48.56 — la reconquête de la 200DMA serait un signal technique majeur. Franchise GLP-1 (Wegovy/Ozempic) reste incontournable malgré la concurrence LLY. EU diversifier géographique avec une corrélation faible au reste du portefeuille (avg rho 0.22).

✅ Confirmations

+6.23% surge with 17M volume — institutional buying confirmed
MACD just crossed positive — trend reversal signal
ATR 3.25% — volatility compression, pre-squeeze pattern
Above EMA20/50, approaching EMA200 at $48.56 — reclaim target
Wegovy/Ozempic franchise — $50B+ GLP-1 market share

❌ Invalidations

Below 200DMA ($48.56) — NOT pure momentum, higher risk
-36% from 52W high ($71.80) — deep recovery play
LLY competitive pressure on GLP-1 market share
CagriSema Phase 3 data risk — binary catalyst
Obesity drug pricing political scrutiny — headline risk

Entry: $45.00–$47.00

Stop Loss: $43.64

TP1: $50.36

TP2: $52.60

R/R: 1:2.0

Horizon: 15 days

Synthesis — 10 Setup Summary

#	Ticker	Name	Region	Strategy	Score	Entry	Stop	TP1	R/R
1	ASML	ASML Holding N.V.	Europe	Momentum	93	$1915	$1803	$2181	1:2.0
2	SMH	VanEck Semiconductor ETF	ETF	Momentum	93	$665	$628	$751	1:2.0
3	CAT	Caterpillar Inc.	US	Momentum	92	$1015	$971	$1124	1:2.0
4	LLY	Eli Lilly and Company	US	Momentum	92	$1090	$1051	$1204	1:2.0
5	ABBV	AbbVie Inc.	US	Momentum	91	$228	$221	$248	1:2.0
6	EWY	iShares MSCI South Korea ETF	APAC	Momentum	91	$216	$203	$252	1:2.0
7	VRTX	Vertex Pharmaceuticals	US	Momentum	90	$463	$449	$503	1:2.0
8	IBB	iShares Biotechnology ETF	ETF	Momentum	89	$175	$171.5	$188	1:2.0
9	UNH	UnitedHealth Group	US	Momentum	88	$403	$393	$435	1:2.0
10	NVO	Novo Nordisk A/S	Europe	Pre-Squeeze	86	$45	$43.64	$50.36	1:2.0

Sector → Strategy → Setup Flow

Portfolio Parameters & Historical Performance

Performance data will be available after the sweep cycle completes.

How to use these levels

Entry zones are ranges — enter at the open (9:30–9:45 ET) if price falls within range. For EU setups, enter at the London open or early US session ADR price. Stop losses are hard exits, not mental stops. TP1 is the primary profit target: take 50% off at TP1, move stop to breakeven, trail the remainder to TP2. R/R ratios assume entry at the midpoint of the range. Horizon is the expected time to TP1 — if TP1 is not hit within 2× the horizon, reassess.

Methodology

1. Market Regime Detection

We compute a composite regime score from 6 components: VIX (sub-20 = 0 = bullish), SPX breadth (above 50/200 DMA), Credit (HYG spread normalization), DXY (weak dollar = bullish for multinationals), Liquidity (Fed balance sheet trend), and TLT (bond market signal). Score range 0–1: 0–0.30 = RISK-ON, 0.30–0.50 = NEUTRAL/Early Risk-Off, 0.50–0.70 = RISK-OFF, >0.70 = DEEP RISK-OFF. The VIX close behavior is the primary confirmation signal.

2. Multi-Strategy Screening

We run 3 complementary DSL screens: (a) Momentum Expansion: close>sma(close,20) && vol>sma(vol,20)*1.5 && rsi14>50 && rsi14<75, (b) Breakout Squeeze: close>sma(close,50) && atr(14)>atr(28)*1.2, (c) Pullback-to-Support: rsi14<45 && close>sma(close,200) && close<sma(close,50)*1.05. Screened universe: US mega-caps, EU/ADR large-caps, Asian ADRs, and sector ETFs. Short Squeeze is excluded from all screens per protocol established March 20, 2026.

3. Composite Scoring (4 Factors)

Each setup receives a score 0–100 based on: Technical (40%) — RSI position, MACD signal, SMA alignment, volume vs average; Momentum (30%) — 1-week, 1-month, 3-month price performance; Confluence (20%) — number of independent signals aligned (min 3 required for A+); Catalyst (10%) — identifiable near-term catalyst (earnings, sector rotation, macro event). Only setups scoring ≥85 qualify as A+.

4. Anti-Dilution & Quality Filter

All selected tickers are vetted for dilution risk: no S-3 shelf registrations, ATM programs, PIPE structures, or aggressive underwriter relationships. Short Squeeze permanently excluded. Open-position exclusions applied per current portfolio state.

5. Validation & Ranking

Final ranking prioritizes: (1) earnings catalyst recency/quality, (2) geopolitical/macro thematic alignment, (3) momentum quality, (4) diversification requirements (min 5 US, 2 EU, 1 Asia, 2 ETF). R/R minimum of 1:1.5 enforced for all setups. Sharia compliance tagged on every setup.

Data Sources

Price data: Yahoo Finance (via DailyTickers Gateway)
Market regime: DailyTickers RunAutoScreener (6-component model)
Screening: RunScreener DSL (3 strategies: momentum, breakout, pullback)
Fundamental data: MCP QueryData (quote, social_sentiment, capital_flow, insider_transactions)
Generated: Tuesday, June 23, 2026

Disclaimer

This scanner is for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security.

All setups carry risk. Past performance of the DailyTickers scanner does not guarantee future results. Entry zones, stops, and targets are estimates based on technical analysis and are not guarantees of execution. Market conditions can change rapidly.

DailyTickers is not a registered investment advisor. All content is provided “as is” without warranty of any kind. Always consult a qualified financial advisor before making investment decisions.

Scanner DailyTickers — Tuesday, June 23, 2026

Market Regime: RISK-OFF (Score 0.38)

Market Snapshot (Tuesday, June 23, 2026)

Why EARLY RISK-OFF demands R/R ≥ 2.0 and H15 horizon

Visual Overview — 10 Setups

Macro Context — Week of Tuesday, June 23, 2026

Global Events Calendar

Sector Rotation Scorecard

Week-Ahead Thesis

#1 ASML — ASML Holding N.V.

ASML — ASML Holding N.V.

✅ Confirmations

❌ Invalidations

#2 SMH — VanEck Semiconductor ETF

SMH — VanEck Semiconductor ETF

✅ Confirmations

❌ Invalidations

#3 CAT — Caterpillar Inc.

CAT — Caterpillar Inc.

✅ Confirmations

❌ Invalidations

#4 LLY — Eli Lilly and Company

LLY — Eli Lilly and Company

✅ Confirmations

❌ Invalidations

#5 ABBV — AbbVie Inc.

ABBV — AbbVie Inc.

✅ Confirmations

❌ Invalidations

#6 EWY — iShares MSCI South Korea ETF

EWY — iShares MSCI South Korea ETF

✅ Confirmations

❌ Invalidations

#7 VRTX — Vertex Pharmaceuticals

VRTX — Vertex Pharmaceuticals

✅ Confirmations

❌ Invalidations

#8 IBB — iShares Biotechnology ETF

IBB — iShares Biotechnology ETF

✅ Confirmations

❌ Invalidations

#9 UNH — UnitedHealth Group

UNH — UnitedHealth Group

✅ Confirmations

❌ Invalidations

#10 NVO — Novo Nordisk A/S

NVO — Novo Nordisk A/S

✅ Confirmations

❌ Invalidations

Synthesis — 10 Setup Summary

Sector → Strategy → Setup Flow

Portfolio Parameters & Historical Performance

How to use these levels

Methodology

1. Market Regime Detection

2. Multi-Strategy Screening

3. Composite Scoring (4 Factors)

4. Anti-Dilution & Quality Filter

5. Validation & Ranking

Data Sources

Disclaimer